CCR2 and melanoma: CCR2 appears to be an attractive target in melanoma and potentially in other tumor types and a CCR2 antibody, plozalizumab, is currently being tested in phase I clinical trial (NCT02723006) in combination with an immune checkpoint blocker, nivolumab.